Search clinical trials for: glatiramer acetate with placebo

Total 1604 results

Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Safety and Efficacy Study of Copaxone Administered in Combination With Minocycline

Relapse Remitting Multiple Sclerosis
Synthon BV

Completed

Efficacy and Safety of GTR in Comparison to Copaxone® (GATE)

Multiple Sclerosis

United States, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Georgia, Germany, Italy, Mexico, Moldova, Republic of, Poland, Romania, Russian Federation, Serbia, South Africa, Ukraine, United Kingdom
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome (PreCISe)

Multiple Sclerosis
Tel-Aviv Sourasky Medical Center
Teva Branded Pharmaceutical Products R&D, Inc.; Medtronic - MITG

Unknown

A Double Blind Placebo Control Study to Assess the Safety,Tolerability and Efficacy of Copaxone in Crohn's Disease (Cop1CD)

Crohns Disease

Israel
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose

Relapse-Remitting Multiple Sclerosis

United States
Teva Neuroscience, Inc.

Completed

A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections of Copaxone®

Multiple Sclerosis

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo (GALA)

Relapsing Remitting Multiple Sclerosis

United States, Bulgaria, Croatia, Czechia, Estonia, Georgia, Germany, Hungary, Israel, Italy, Lithuania, Poland, Romania, Russian Federation, South Africa, Ukraine, United Kingdom
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an Antihistamine (Zyrtec®) or Placebo Prior to Daily Injections of Copaxone®.

Multiple Sclerosis
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).

Relapsing Remitting Multiple Sclerosis
Teva Pharmaceutical Industries, Ltd.

Completed

Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

Belgium, France, Germany, Israel, Italy, United Kingdom
Teva Neuroscience, Inc.

Completed

Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients (ENCORE)

Multiple Sclerosis
Federal University of São Paulo

Unknown

Effects of Copaxone in the Retinal Function in Diabetic Patients After Panphotocoagulation

Diabetic Retinopathy

Brazil
Sanofi

Completed

FOCUS Fatigue Outcome in Copaxone USers

Multiple Sclerosis

Czech Republic
Sheba Medical Center

Unknown

Gait Evaluation in Multiple Sclerosis Patients Treated With Glatiramer Acetate

Multiple Sclerosis

Israel
Amphia Hospital
Sanofi; TEVA Pharmachemie

Unknown

Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS) (OCTIMS)

Multiple Sclerosis

Netherlands
Kaplan Medical Center

Unknown

Copaxone in Age Related Macular Degeneration

Macular Degeneration

Israel
Singapore Eye Research Institute

Unknown

Investigating the Neuroprotective Effect of Cop-1 (Copaxone) in Acute Primary Angle Closure

Glaucoma, Angle-closure, Primary, Acute

Singapore
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness

Relapsing-Remitting Multiple Sclerosis

United States
University of Kansas Medical Center

Active, not recruiting

A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible Tumors

Basal Cell Carcinoma | Squamous Cell Carcinoma | Cutaneous Squamous Cell Carcinoma

United States
Sheba Medical Center

Unknown

An Open Label, Exploratory Study to Investigate the Treatment Effect of Glatiramer Acetate on Girls Woth Rett Syndrome

Rett Syndrome

Israel
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis.

Relapsing Remitting Multiple Sclerosis
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Safety of New Formulation of Glatiramer Acetate (Song)

Relapsing Remitting Multiple Sclerosis
University of California, San Francisco
National Multiple Sclerosis Society; Teva Neuroscience, Inc.

Completed

Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis

Multiple Sclerosis

United States
Takeda

Active, not recruiting

Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) "Prevention of Relapse of Multiple Sclerosis"

Multiple Sclerosis

Japan
Biocad

Completed

Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis

Relapsing-remitting Multiple Sclerosis
University of California, Los Angeles
Johns Hopkins University; University of Colorado, Denver; Mayo Clinic; University... and other collaborators

Completed

A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS) (Estriol-MS)

Relapsing Remitting Multiple Sclerosis

United States, Canada
University at Buffalo
Teva Neuroscience, Inc.

Completed

Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA)

Multiple Sclerosis

United States
Neurognostics

Terminated

An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis

Relapsing-Remitting Multiple Sclerosis

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Withdrawn

A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability

Relapsing Multiple Sclerosis
Fred Lublin
National Institute of Neurological Disorders and Stroke (NINDS)

Completed

Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx

Relapsing Remitting Multiple Sclerosis

United States, Canada
Pfizer

Completed

Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease

Crohn's Disease

United States, Spain, Lebanon, Australia, Russian Federation, Korea, Republic of, Tunisia, Italy, Poland, Belgium, Austria, Germany, Saudi Arabia, Czechia, Hungary, Switzerland, Turkey, Slovakia, Ukraine, Georgia, Bosnia and Herzegovina and more
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon)

Optic Neuritis
Johns Hopkins University

Withdrawn

High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis (HiCy)

Relapsing Remitting Multiple Sclerosis

United States
Novartis Pharmaceuticals

Terminated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone (ASSESS)

Relapsing-remitting Multiple Sclerosis (RRMS)

United States, Canada, Mexico, Brazil, Puerto Rico, Argentina, Chile
Sanofi

Completed

Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis

Multiple Sclerosis

United States, Canada, Germany, United Kingdom, Austria, Italy
University of Turku
Chr Hansen; Fennobon oy, Karkkila, Finland (provides the tablets for the pacifier) and other collaborators

Completed

Bifidobacterium Lactis BB12 and Xylitol Delivered With a Novel Slow-release Pacifier

Dental Caries | Infectious Diseases

Finland
EMD Serono

Terminated

Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)

Relapsing Remitting Multiple Sclerosis

United States, Croatia, Bulgaria, Czech Republic, Italy, Mexico, Russian Federation, South Africa, Spain, Turkey, Hungary, Poland, Ukraine, Finland, United Kingdom, Greece, Serbia
Novartis Pharmaceuticals

Completed

A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

Relapsing Multiple Sclerosis (RMS)

United States
The New York Eye & Ear Infirmary

Suspended

Weekly Vaccination With Copaxone as a Potential Therapy for Dry Age-related Macular Degeneration

Dry Age Related Macular Degeneration

United States
Biogen

Withdrawn

Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)

Relapsing Multiple Sclerosis
Novartis Pharmaceuticals

Recruiting

A NIS Evaluating Injectable Treatments in Patients With Relapsing Multiple Sclerosis (AIOLOS)

Relapsing Multiple Sclerosis

Germany
EMD Serono
Pfizer

Completed

Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis

Relapsing-remitting Multiple Sclerosis

United States, United Kingdom, Argentina, Austria, Brazil, France, Germany, Italy, Netherlands, Russian Federation, Spain, Switzerland
Teva Branded Pharmaceutical Products R&D, Inc.

Terminated

An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) (GLOW)

Relapsing-Remitting Multiple Sclerosis

United States, Albania, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Estonia, Georgia, Greece, Latvia, Macedonia, The Former Yugoslav Republic of, Mexico, Moldova, Republic of, Montenegro, Poland, Romania, Russian... and more
Transgene

Terminated

Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal Cancer

Colorectal Neoplasms

France, United Kingdom
National Institute of Allergy and Infectious Diseases...
Autoimmunity Centers of Excellence

Completed

Treatment of Multiple Sclerosis With Copaxone and Albuterol

Multiple Sclerosis | Autoimmune Diseases

United States
Biogen
Elan Pharmaceuticals

Terminated

Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis (SURPASS)

Relapsing Remitting Multiple Sclerosis

United States, Czech Republic, Italy, Spain, Sweden, Latvia, Finland, Hungary, Poland, Slovenia, Australia, Canada, France
Nancy Hammond, MD
Kansas City Area Life Sciences Institute, Inc.

Completed

Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis

Multiple Sclerosis | Low Bone Density

United States
University of Medicine and Dentistry of New Jersey

Completed

Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI (BECOME)

Multiple Sclerosis

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Safety and Efficacy Study of Copaxone Administered in Combination With N-Acetylcysteine

Relapse Remitting Multiple Sclerosis
Transgene

Terminated

Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors.

Colorectal Neoplasm | Digestive System Neoplasm

France, Spain, Belgium

Search clinical trials for: glatiramer acetate with placebo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations